Abstract:There have been significant advances in the treatment of urology cancers, with a number of practice‐changing treatments. There is now greater clarity on the role of the use of immunotherapies in renal cell carcinoma. The use of triplet combinations with immune checkpoint inhibition with anti‐vascular endothelial growth factor tyrosine kinase inhibitors in the front‐line setting for metastatic disease (COSMIC313) has been explored. The use of adjuvant therapy has been complicated by a series of negative immune therapy trials. Promising results with the HIF‐2α transcription factor inhibitor, belzutifan, alone or in combination with other agents, have been reported. Antibody drug conjugates, including enfortumab vedotin and sacituzumab govitecan, have continued to show activity in urothelial cancer with promising clinical outcomes. This has led to further exploration of the combination of these novel agents with immunotherapy and accelerated Food and Drug Administration approvals. Data are also discussed regarding intensification for front‐line therapy of metastatic castrate sensitive prostate cancer. The combination of androgen‐signaling inhibitors, docetaxel, and androgen deprivation therapy (PEACE‐1, ARASENS), as well as the use of abiraterone acetate for adjuvant therapy in high‐risk disease (STAMPEDE), is included. There is also growing evidence for the use of the radioligand therapy 177Lu‐PSMA‐617 in metastatic castrate resistant disease, with an established overall survival benefit in this patient population (VISION, TheraP). Plain Language Summary There have been many advancements in the treatment of cancers of the kidney, bladder, and prostate in the past year. Several studies using new therapies or new combinations of therapies have improved the chances of patients living longer with these cancers, especially those with advanced disease. Here, we discuss a selection of the most compelling recently published data that have changed the way these cancers are treated, as well as those that are expected to change treatment in the near future.

[The Clinical Focus and Prospect of Medical Treatments in Genitourinary Tract Tumors].

Top advances of the year: Genitourinary cancer

Current status and perspective of the immunotherapy of urologic cancer

Immunotherapeutic prospects and progress in bladder cancer

Recent Advances in Imaging-Guided Interventions for Prostate Cancers.

Advances in bladder cancer biology and therapy

Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies

The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

Advances in diagnosis and treatment of bladder cancer

Paradigm Shifting Research: Key Studies in Urologic Oncology

Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors

Advances in the Treatment of Kidney and Upper Urinary Tract Cancers

Systemic therapy for bladder cancer finally comes into a new age

Progress in Diagnosis and Treatment of Gynecological Tumors in 2022

Advances and future prospects of immunotherapy in bladder cancer

Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors

Editorial: The mechanism of tumor evolution and microenvironmental changes of genitourinary oncology in clinical diagnosis and treatment

Recent advances for treatment of upper gastrointestinal malignancy

Recent Advance of Nanomaterial-Mediated Tumor Therapies in the Past Five Years

Recent Advances in the Treatment of Pancreatic Cancer

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer